Apotea

Adoption of the income statement and balance sheet

The AGM adopted the income statement and balance, as well as the consolidated income statement and consolidated balance sheet, for the financial year of 2024.

Dispositions regarding the Company’s result

The AGM resolved, in accordance with the board of directors’ proposal, that no dividend is to be paid for the financial year of 2024 and that the Company's available funds, including the year's profit, shall be carried forward.

Discharge of liability for the members of the board of directors and the managing director

The AGM resolved to discharge each of the members of the board of directors and the managing director active during the financial year of 2024 from liability for their administration of the Company’s operations during the financial year of 2024.

Establishment of the number of board members and auditors

The AGM resolved, in accordance with the nomination committee's proposal, that the board of directors, up until the next annual general meeting, shall consist of seven (7) directors without deputies and that the Company shall have one (1) auditor or one (1) audit firm without a deputy auditor.

Board and Auditor Fees

The AGM resolved, in accordance with the nomination committee’s proposal, that fees to the board of directors and the auditor, for the period up until the next annual general meeting, shall be paid as follows:

Fees to the board of directors shall be paid in the total amount of maximum SEK 3,121,875 (3,150,000), whereof

• SEK 725,000 (600,000) shall be paid to the chairman of the board;
• SEK 325,000 (300,000) shall be paid to each of the other directors who are not employed by the Company; and
• The auditor's fee shall be paid on current account for work performed.

In addition to fees to the board of directors and the auditor, the AGM resolved that fees shall be paid to members of the board's audit and remuneration committees as follows for the period up until the next annual general meeting:

• SEK 162,500 (150,000) to the chairman of the board's audit committee;
• SEK 81,250 (75,000) to each of the other members of the audit committee;
• SEK 81,250 (75,000) to the chairman of the board's remuneration committee; and
• SEK 40,625 (37,500) to each of the other members of the remuneration committee.

Election of board of directors, chairman of the board, and auditor

The AGM resolved, in accordance with the nomination committee’s proposal, to re-elect Cecilia Qvist, Anders Eriksson, Joanna Hummel, Jonas Hagströmer, Monica Lindstedt, Per Schlingmann, and Pär Svärdson as members of the board of directors for the period up until the next annual general meeting. The AGM further resolved, in accordance with the nomination committee’s proposal, to re-elect Cecilia Qvist as chairman of the board.

It was noted that the former board members Maria Curman and Henrik Forsberg Schoultz have declined re-election.

The AGM further resolved, in accordance with the nomination committee’s proposal, to re-elect the registered audit firm Öhlrings PricewaterhouseCoopers AB as the Company's auditor for the period up until the next annual general meeting, with the authorized public accountant Tobias Stråhle as principal auditor.

Nomination committee ahead of the AGM 2026

The AGM resolved, in accordance with the nomination committee’s proposal, to adopt instructions for the nomination committee and principles for the appointment of the nomination committee ahead of the AGM 2026. These briefly entail that the nomination committee shall consist of representatives appointed by the four (4) largest shareholders in the Company as of the last banking day of August of each year, together with the chairman of the board.

Remuneration report

The AGM resolved, in accordance with the board of directors' proposal, to approve the board of directors' remuneration report for 2024.

Authorization for the board of directors to resolve to issue shares, convertibles and/or warrants

The AGM resolved, in accordance with the board of directors’ proposal, to authorize the board of directors for the period up until the next annual general meeting, on one or more occasions and with or without deviation from the shareholders' preferential rights, to resolve on an increase of the Company's share capital through new issues of shares, convertibles and/or warrants. Payment shall be made in cash, in kind, by set-off or otherwise in accordance with terms. The Company's share capital and number of shares may, under the authorization, be increased by an amount and number corresponding to a maximum dilution of ten (10) percent of the share capital in the Company.

The purpose of the authorization and the reasons for any deviation from the shareholders' preferential rights is to enable issues to meet the Company's capital requirements and secure the Company's continued operations and development as well as to carry out acquisitions. In the event of a deviation from the shareholders' preferential rights, the issue shall be made on market terms, however, with the possibility of granting a market-based discount.

The authorization shall be valid until the next annual general meeting of the Company.

For more detailed information on the content of the resolutions, please refer to the notice and the board of directors’ and nomination committee’s complete proposals for resolutions, which are available on the Company's website, https://ir.apotea.se/gov/bolagsstämmor/årsstämma2025. Minutes from the AGM will also be published shortly on the Company's website.

For further information, please contact:
Stefan Eriksson, deputy CEO & Investor Relations
E-mail: ir@apotea.se

About Apotea
Apotea is Sweden’s leading online pharmacy by market share with the goal of becoming the largest pharmacy in Sweden and hence also in the Nordics. With the widest assortment on the market, low prices and quick deliveries, Apotea facilitates everyday life for its three million active customers. In E-barometern’s 2024 customer survey, Apotea was ranked as customers’ favourite e-commerce store for the seventh consecutive year. Since 2022, the group also operates in Norway through its Norwegian subsidiary Apotera.